JP6022063B2 - ヤヌスキナーゼ（ｊａｋ）阻害剤の投与計画 - Google Patents

ヤヌスキナーゼ（ｊａｋ）阻害剤の投与計画 Download PDF

Info

Publication number
JP6022063B2
JP6022063B2 JP2015523243A JP2015523243A JP6022063B2 JP 6022063 B2 JP6022063 B2 JP 6022063B2 JP 2015523243 A JP2015523243 A JP 2015523243A JP 2015523243 A JP2015523243 A JP 2015523243A JP 6022063 B2 JP6022063 B2 JP 6022063B2
Authority
JP
Japan
Prior art keywords
therapeutically effective
jak
administration
day
effective dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015523243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522620A (ja
Inventor
ゴンザレス，アンドレア・ジェイ
コスグローブ，サリー・ビー
マルパス，フィリス・ビー
シュテーゲマン，ミヒャエル・ロルフ
コラード，ウェンディ・ターナー
Original Assignee
ゾエティス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6022063(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ゾエティス・エルエルシー filed Critical ゾエティス・エルエルシー
Publication of JP2015522620A publication Critical patent/JP2015522620A/ja
Application granted granted Critical
Publication of JP6022063B2 publication Critical patent/JP6022063B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2015523243A 2012-07-20 2013-07-18 ヤヌスキナーゼ（ｊａｋ）阻害剤の投与計画 Active JP6022063B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US61/674,289 2012-07-20
US201361815803P 2013-04-25 2013-04-25
US61/815,803 2013-04-25
PCT/US2013/051015 WO2014015107A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016154135A Division JP2017019816A (ja) 2012-07-20 2016-08-05 ヤヌスキナーゼ（ｊａｋ）阻害剤の投与計画

Publications (2)

Publication Number Publication Date
JP2015522620A JP2015522620A (ja) 2015-08-06
JP6022063B2 true JP6022063B2 (ja) 2016-11-09

Family

ID=48901189

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015523243A Active JP6022063B2 (ja) 2012-07-20 2013-07-18 ヤヌスキナーゼ（ｊａｋ）阻害剤の投与計画
JP2016154135A Pending JP2017019816A (ja) 2012-07-20 2016-08-05 ヤヌスキナーゼ（ｊａｋ）阻害剤の投与計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016154135A Pending JP2017019816A (ja) 2012-07-20 2016-08-05 ヤヌスキナーゼ（ｊａｋ）阻害剤の投与計画

Country Status (25)

Country Link
US (1) US9522151B2 (https=)
EP (1) EP2874630B1 (https=)
JP (2) JP6022063B2 (https=)
KR (2) KR20150028299A (https=)
CN (2) CN104470525A (https=)
AU (1) AU2013292547B2 (https=)
BR (1) BR112015000808A2 (https=)
CA (1) CA2878867C (https=)
CY (1) CY1121436T1 (https=)
DK (1) DK2874630T3 (https=)
ES (1) ES2707627T3 (https=)
HK (2) HK1209314A1 (https=)
HR (1) HRP20182088T1 (https=)
HU (1) HUE042771T2 (https=)
IN (1) IN2015DN00370A (https=)
LT (1) LT2874630T (https=)
MX (1) MX360857B (https=)
NZ (1) NZ703152A (https=)
PL (1) PL2874630T3 (https=)
PT (1) PT2874630T (https=)
RS (1) RS58242B1 (https=)
SI (1) SI2874630T1 (https=)
SM (1) SMT201900044T1 (https=)
WO (1) WO2014015107A1 (https=)
ZA (1) ZA201500134B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24275B1 (es) 2013-02-22 2017-10-05 Pfizer Derivados de cicloalquilo pirrolo [2,3-d] pirimidina-4-il amino útiles como inhibidores de quinasas janus relacionadas y composiciones farmacéuticas que contienen tales compuestos
EP3180344B1 (en) 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
EP3362455A1 (en) 2015-10-16 2018-08-22 AbbVie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2017143014A1 (en) * 2016-02-16 2017-08-24 Brian Kim Jak inhibitors and uses thereof
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
WO2020155931A1 (zh) 2019-01-30 2020-08-06 格格巫（珠海）生物科技有限公司 一种jak抑制剂及其制备方法
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN117242080A (zh) 2020-12-18 2023-12-15 勃林格殷格翰动物保健美国公司 含硼吡唑化合物、包括其的组合物、其方法和用途
EP4310085A4 (en) * 2021-03-16 2025-09-24 Hk Inno N Corp NOVEL SALTS OF HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR AND USES THEREOF
CN117136059A (zh) * 2021-04-22 2023-11-28 深圳微芯生物科技股份有限公司 包含jak3/jak1/tbk1选择性抑制剂的药物组合物及其医药用途
WO2024259429A2 (en) * 2023-06-16 2024-12-19 The University Of Chicago Methods and compositions for pharmaceutically relevant interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9911365A (pt) * 1998-06-19 2001-03-13 Pfizer Prod Inc Compostos pirrolo[2,3-d]pirimidina
JP4884570B2 (ja) * 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物

Also Published As

Publication number Publication date
HK1209314A1 (en) 2016-04-01
CY1121436T1 (el) 2020-05-29
PL2874630T3 (pl) 2019-04-30
AU2013292547A1 (en) 2015-01-22
AU2013292547B2 (en) 2017-05-04
ZA201500134B (en) 2016-08-31
RS58242B1 (sr) 2019-03-29
WO2014015107A1 (en) 2014-01-23
US9522151B2 (en) 2016-12-20
NZ703152A (en) 2016-03-31
US20150126535A1 (en) 2015-05-07
KR20170034949A (ko) 2017-03-29
SI2874630T1 (sl) 2019-04-30
ES2707627T3 (es) 2019-04-04
IN2015DN00370A (https=) 2015-06-12
PT2874630T (pt) 2019-01-31
DK2874630T3 (en) 2019-01-28
JP2015522620A (ja) 2015-08-06
BR112015000808A2 (pt) 2017-06-27
HK1252083A1 (zh) 2019-05-17
SMT201900044T1 (it) 2019-02-28
HRP20182088T1 (hr) 2019-02-08
HUE042771T2 (hu) 2019-07-29
EP2874630A1 (en) 2015-05-27
CA2878867C (en) 2018-01-09
MX360857B (es) 2018-11-20
CN108354938A (zh) 2018-08-03
MX2015000871A (es) 2015-05-07
CN104470525A (zh) 2015-03-25
CA2878867A1 (en) 2014-01-23
EP2874630B1 (en) 2018-12-05
JP2017019816A (ja) 2017-01-26
LT2874630T (lt) 2019-02-11
KR20150028299A (ko) 2015-03-13

Similar Documents

Publication Publication Date Title
JP6022063B2 (ja) ヤヌスキナーゼ（ｊａｋ）阻害剤の投与計画
US11318151B2 (en) Compound pharmaceutical composition for treating skin inflammatory diseases
AU2020347561B2 (en) Treatment of hidradenitis with JAK inhibitors
CN118201616A (zh) 用于癌症的wee1抑制剂
US20240075038A1 (en) Application of pyrido[1,2-a]pyrimidinone analog
CN101380317B (zh) 减缓搔痒症的药学组合物
KR20240009964A (ko) 결절성 양진 치료를 위한 jak1 경로 억제제
CN116744923B (zh) 普利多匹定及类似物用于治疗rett综合征的用途
CN118984704A (zh) 治疗卵巢癌的药物组合和方法
US20240091229A1 (en) Use of pyrido[1,2-a]pyrimidone analogue
US20230293544A1 (en) Methods, dosage regimens, and compositions for treating hidradenitis
EP0505640B2 (en) Improved therapeutic method
HK40115079A (zh) 用於治疗汗腺炎的方法、剂量方案和组合物
US20230416244A1 (en) Imidazoquinoline compound having anti-inflammatory, antifugal, antiparasitic, and anticancer activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150122

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160805

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161004

R150 Certificate of patent or registration of utility model

Ref document number: 6022063

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250